Sadjak A, Supanz S, Korsatko W, Erhart U, Muhry F
Universitätsinstitut für Funktionelle Pathologie, Karl-Franzens-Universität Graz, Austria.
Agents Actions. 1988 Jun;24(1-2):210-4. doi: 10.1007/BF01968103.
As a further step in the development of implantable retard systems for simultaneous delivery of inulin and PAH, a system based on Eudragit matrix retard tablet has been deviced. It should be able to release a sufficient amount of both substances to maintain constant and well measurable serum and urine concentration in the 36 hours interval between 12-48 hours p.o. The feasibility of the technique was checked by monitoring the behaviour of renal function after administration of a permanent adrenaline application, which we used as a well defined noxa.